MaaT Pharma’s 18-month struggle to get out from under an FDA clinical hold may be entering its endgame. In its latest feedback, the agency reportedly agreed to a list of conditions that could enable ...

A year after a long-running clinical hold was lifted on MaaT Pharma’s pooled fecal therapy, the microbiome biotech has touted 18-month data as proof it’s on track to launch the drug in acute ...

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for ...

In June 2025, the European Medicines Agency accepted for review the marketing authorization submission for this medicine MaaT Pharma will receive a €10.5 million upfront payment, further potential ...

LYON, France--(BUSINESS WIRE)--Regulatory News: These encouraging findings from the IASO Phase 1b trial confirm the favorable safety and tolerability profile of MaaT033 in ALS patients. They also ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

MaaT Pharma is charting new territory in oncology by positioning microbiome-driven therapy as a potentially promising new pillar alongside traditional treatments. In this discussion, CEO and ...

LYON, France--(BUSINESS WIRE)--$MAAT #Cancer--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader ...

LYON, France--(BUSINESS WIRE)--$MAAT #ASH--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in ...

LYON, France, May 12, 2025--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome ...